Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Reassessing the Association between Circulating Vitamin D and IGFBP-3: Observational and Mendelian Randomization Estimates from Independent Sources.

Tan VY, Biernacka KM, Dudding T, Bonilla C, Gilbert R, Kaplan RC, Qibin Q, Teumer A, Martin RM, Perks CM, Timpson NJ, Holly JMP; PRACTICAL consortium.

Cancer Epidemiol Biomarkers Prev. 2018 Dec;27(12):1462-1471. doi: 10.1158/1055-9965.EPI-18-0113. Epub 2018 Aug 2.

PMID:
30072546
2.

Insulin-like Growth Factor II (IGF-II) in Adipocyte Regulation: Depot-Specific Actions Suggest a Potential Role Limiting Excess Visceral Adiposity.

Alfares MN, Perks CM, Hamilton-Shield JP, Holly JMP.

Am J Physiol Endocrinol Metab. 2018 Jul 24. doi: 10.1152/ajpendo.00409.2017. [Epub ahead of print]

PMID:
30040480
3.

Inhibition of FASN and ERα signalling during hyperglycaemia-induced matrix-specific EMT promotes breast cancer cell invasion via a caveolin-1-dependent mechanism.

Zielinska HA, Holly JMP, Bahl A, Perks CM.

Cancer Lett. 2018 Apr 10;419:187-202. doi: 10.1016/j.canlet.2018.01.028. Epub 2018 Jan 11.

4.

Hyperglycemia Promotes TMPRSS2-ERG Gene Fusion in Prostate Cancer Cells via Upregulating Insulin-Like Growth Factor-Binding Protein-2.

Holly JMP, Broadhurst J, Mansor R, Bahl A, Perks CM.

Front Endocrinol (Lausanne). 2017 Nov 6;8:305. doi: 10.3389/fendo.2017.00305. eCollection 2017.

5.

Developing the WCRF International/University of Bristol Methodology for Identifying and Carrying Out Systematic Reviews of Mechanisms of Exposure-Cancer Associations.

Lewis SJ, Gardner M, Higgins J, Holly JMP, Gaunt TR, Perks CM, Turner SD, Rinaldi S, Thomas S, Harrison S, Lennon RJ, Tan V, Borwick C, Emmett P, Jeffreys M, Northstone K, Mitrou G, Wiseman M, Thompson R, Martin RM.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1667-1675. doi: 10.1158/1055-9965.EPI-17-0232. Epub 2017 Oct 4.

6.

Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.

Biernacka KM, Persad RA, Bahl A, Gillatt D, Holly JM, Perks CM.

Endocr Relat Cancer. 2017 Jan;24(1):17-30. Epub 2016 Oct 17.

7.

Insulin Receptor Isoform Variations in Prostate Cancer Cells.

Perks CM, Zielinska HA, Wang J, Jarrett C, Frankow A, Ladomery MR, Bahl A, Rhodes A, Oxley J, Holly JM.

Front Endocrinol (Lausanne). 2016 Sep 28;7:132. eCollection 2016.

8.

Blood lipids and prostate cancer: a Mendelian randomization analysis.

Bull CJ, Bonilla C, Holly JM, Perks CM, Davies N, Haycock P, Yu OH, Richards JB, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, MacInnis RJ, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Micheal A, Pandha H, Smith GD, Lewis SJ, Martin RM; PRACTICAL consortium.

Cancer Med. 2016 Jun;5(6):1125-36. doi: 10.1002/cam4.695. Epub 2016 Mar 19.

9.

Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial.

Hackshaw-McGeagh L, Lane JA, Persad R, Gillatt D, Holly JM, Koupparis A, Rowe E, Johnston L, Cloete J, Shiridzinomwa C, Abrams P, Penfold CM, Bahl A, Oxley J, Perks CM, Martin R.

Trials. 2016 Mar 7;17(1):123. doi: 10.1186/s13063-016-1248-x.

10.

Hyperglycaemia-induced chemoresistance in breast cancer cells: role of the estrogen receptor.

Zeng L, Zielinska HA, Arshad A, Shield JP, Bahl A, Holly JM, Perks CM.

Endocr Relat Cancer. 2016 Feb;23(2):125-34. doi: 10.1530/ERC-15-0507. Epub 2015 Dec 8.

PMID:
26647383
11.

Epigenetic regulation of insulin-like growth factor binding protein-3 (IGFBP-3) in cancer.

Perks CM, Holly JM.

J Cell Commun Signal. 2015 Jun;9(2):159-66. doi: 10.1007/s12079-015-0294-6. Epub 2015 Apr 29.

12.

Caffeine and Caffeic Acid Inhibit Growth and Modify Estrogen Receptor and Insulin-like Growth Factor I Receptor Levels in Human Breast Cancer.

Rosendahl AH, Perks CM, Zeng L, Markkula A, Simonsson M, Rose C, Ingvar C, Holly JM, Jernström H.

Clin Cancer Res. 2015 Apr 15;21(8):1877-87. doi: 10.1158/1078-0432.CCR-14-1748. Epub 2015 Feb 17.

13.

IGFBP-2/PTEN: A critical interaction for tumours and for general physiology?

Zeng L, Perks CM, Holly JM.

Growth Horm IGF Res. 2015 Jun;25(3):103-7. doi: 10.1016/j.ghir.2015.01.003. Epub 2015 Feb 8. Review.

PMID:
25683897
14.

Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?

Zielinska HA, Bahl A, Holly JM, Perks CM.

Breast Cancer (Dove Med Press). 2015 Jan 19;7:9-19. doi: 10.2147/BCTT.S43932. eCollection 2015. Review.

15.

Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells.

Zeng L, Holly JM, Perks CM.

Front Endocrinol (Lausanne). 2014 May 7;5:61. doi: 10.3389/fendo.2014.00061. eCollection 2014.

16.

Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer.

Dean SJ, Perks CM, Holly JM, Bhoo-Pathy N, Looi LM, Mohammed NA, Mun KS, Teo SH, Koobotse MO, Yip CH, Rhodes A.

Am J Clin Pathol. 2014 Mar;141(3):323-33. doi: 10.1309/AJCPR11DEAYPTUSL.

PMID:
24515759
17.

Grand challenges in cancer endocrinology: endocrine related cancers, an expanding concept.

Belfiore A, Perks CM.

Front Endocrinol (Lausanne). 2013 Oct 8;4:141. doi: 10.3389/fendo.2013.00141. eCollection 2013. No abstract available.

18.

Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.

Biernacka KM, Uzoh CC, Zeng L, Persad RA, Bahl A, Gillatt D, Perks CM, Holly JM.

Endocr Relat Cancer. 2013 Sep 11;20(5):741-51. doi: 10.1530/ERC-13-0077. Print 2013 Oct.

PMID:
23959956
19.

Epithelial cancers in the post-genomic era: should we reconsider our lifestyle?

Holly JM, Zeng L, Perks CM.

Cancer Metastasis Rev. 2013 Dec;32(3-4):673-705. doi: 10.1007/s10555-013-9445-5. Review.

20.

Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells.

Zeng L, Jarrett C, Brown K, Gillespie KM, Holly JM, Perks CM.

Exp Cell Res. 2013 Aug 15;319(14):2282-95. doi: 10.1016/j.yexcr.2013.06.011. Epub 2013 Jun 26.

PMID:
23810988
21.

Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor.

Foulstone EJ, Zeng L, Perks CM, Holly JM.

Endocrinology. 2013 May;154(5):1780-93. doi: 10.1210/en.2012-1970. Epub 2013 Mar 20.

PMID:
23515291
22.

Insulin-like growth factor-II is produced by, signals to and is an important survival factor for the mature podocyte in man and mouse.

Hale LJ, Welsh GI, Perks CM, Hurcombe JA, Moore S, Hers I, Saleem MA, Mathieson PW, Murphy AJ, Jeansson M, Holly JM, Hardouin SN, Coward RJ.

J Pathol. 2013 May;230(1):95-106. doi: 10.1002/path.4165. Epub 2013 Mar 21.

PMID:
23299523
23.

Role of the IGF axis in prostate cancer.

Biernacka KM, Perks CM, Holly JM.

Minerva Endocrinol. 2012 Jun;37(2):173-85. Review.

PMID:
22691890
24.

Insulin-like growth factors in health and disease. Preface.

Perks CM, Holly JM.

Endocrinol Metab Clin North Am. 2012 Jun;41(2):xv-xvi. doi: 10.1016/j.ecl.2012.04.021. Epub 2012 May 15. No abstract available.

PMID:
22682641
25.

Insulin-like growth factor physiology: what we have learned from human studies.

Holly JM, Perks CM.

Endocrinol Metab Clin North Am. 2012 Jun;41(2):249-63, v. doi: 10.1016/j.ecl.2012.04.009. Epub 2012 May 8. Review.

PMID:
22682629
26.

Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival.

Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM, Hanemann CO.

Oncogene. 2012 Mar 29;31(13):1710-22. doi: 10.1038/onc.2011.357. Epub 2011 Sep 5.

PMID:
21892205
27.

Hormonal mechanisms underlying the relationship between obesity and breast cancer.

Perks CM, Holly JM.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):485-507, vii. doi: 10.1016/j.ecl.2011.05.010. Epub 2011 Jul 8. Review.

PMID:
21889716
28.

Green tea extract (epigallocatechin-3-gallate) reduces efficacy of radiotherapy on prostate cancer cells.

Thomas F, Holly JM, Persad R, Bahl A, Perks CM.

Urology. 2011 Aug;78(2):475.e15-21. doi: 10.1016/j.urology.2011.03.031. Epub 2011 Jun 14.

PMID:
21676444
29.

Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.

Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM.

Br J Cancer. 2011 May 10;104(10):1587-93. doi: 10.1038/bjc.2011.127. Epub 2011 Apr 12.

30.

Intrinsic, Pro-Apoptotic Effects of IGFBP-3 on Breast Cancer Cells are Reversible: Involvement of PKA, Rho, and Ceramide.

Perks CM, Burrows C, Holly JM.

Front Endocrinol (Lausanne). 2011 May 16;2:13. doi: 10.3389/fendo.2011.00013. eCollection 2011.

31.

IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin.

McIntosh J, Dennison G, Holly JM, Jarrett C, Frankow A, Foulstone EJ, Winters ZE, Perks CM.

J Biol Chem. 2010 Dec 10;285(50):38788-800. doi: 10.1074/jbc.M110.177311. Epub 2010 Sep 17.

32.

Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase.

Zeng L, Biernacka KM, Holly JM, Jarrett C, Morrison AA, Morgan A, Winters ZE, Foulstone EJ, Shield JP, Perks CM.

Endocr Relat Cancer. 2010 May 18;17(2):539-51. doi: 10.1677/ERC-09-0221. Print 2010 Jun.

PMID:
20356977
33.
34.

PTEN-mediated pathways and their association with treatment-resistant prostate cancer.

Uzoh CC, Perks CM, Bahl A, Holly JM, Sugiono M, Persad RA.

BJU Int. 2009 Aug;104(4):556-61. doi: 10.1111/j.1464-410X.2009.08411.x. Epub 2009 Feb 13. Review. No abstract available.

35.

IGF binding proteins (IGFBPs) and regulation of breast cancer biology.

Perks CM, Holly JM.

J Mammary Gland Biol Neoplasia. 2008 Dec;13(4):455-69. doi: 10.1007/s10911-008-9106-4. Epub 2008 Nov 25. Review.

PMID:
19031049
36.

Cancer as an endocrine problem.

Holly JM, Perks CM.

Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):539-50. doi: 10.1016/j.beem.2008.07.007. Review.

PMID:
18971117
37.

Dihydrotestosterone sensitises LNCaP cells to death induced by epigallocatechin-3-Gallate (EGCG) or an IGF-I receptor inhibitor.

Thomas F, Patel S, Holly JM, Persad R, Bahl A, Perks CM.

Prostate. 2009 Feb 1;69(2):219-24. doi: 10.1002/pros.20873.

PMID:
18942120
38.

How growth hormone may be linked to cancer: concerns and perspective.

Holly JM, Foulstone EJ, Perks CM.

Expert Rev Endocrinol Metab. 2007 Nov;2(6):759-771. doi: 10.1586/17446651.2.6.759.

PMID:
30290467
39.

IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells.

Perks CM, Vernon EG, Rosendahl AH, Tonge D, Holly JM.

Oncogene. 2007 Aug 30;26(40):5966-72. Epub 2007 Mar 19.

PMID:
17369847
40.

Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes.

Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA, McIntosh J, McCaig C, Winters ZE, Perks CM.

Endocrinology. 2006 Jul;147(7):3484-500. Epub 2006 Apr 13.

PMID:
16614079
41.

Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome.

Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M, Winters ZE.

Eur J Cancer. 2005 May;41(7):1017-25.

PMID:
15862750
42.
43.

The insulin-like growth factor (IGF) family and breast cancer.

Perks CM, Holly JM.

Breast Dis. 2003;18:45-60.

PMID:
15687688
44.

IGFBPs and breast cancer.

Perks CM, Holly JM.

Breast Dis. 2003;17:91-104.

PMID:
15687680
45.
46.

p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.

Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M, Winters ZE.

Breast Cancer Res. 2004;6(5):R571-85. Epub 2004 Jul 29.

47.

Prolactin acts as a potent survival factor for human breast cancer cell lines.

Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM.

Br J Cancer. 2004 Jul 19;91(2):305-11.

48.

Prolactin acts as a potent survival factor against C2-ceramide-induced apoptosis in human granulosa cells.

Perks CM, Newcomb PV, Grohmann M, Wright RJ, Mason HD, Holly JM.

Hum Reprod. 2003 Dec;18(12):2672-7.

PMID:
14645190
49.

Role of the IGF-II receptor in mediating acute, non-genomic effects of retinoids and IGF-II on keratinocyte cell death.

Louafi F, Stewart CE, Perks CM, Thomas MG, Holly JM.

Exp Dermatol. 2003 Aug;12(4):426-34.

PMID:
12930299
50.

Supplemental Content

Loading ...
Support Center